Mansoor Karimifar
1*, Mozhgan Karimifar
21 Department of Rheumatology, Isfahan University of Medical Sciences, Isfahan, Iran.
2 Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract
Implication for health policy/practice/research/medical education
Treatment for renal failure, especially those who undergo dialysis, is very difficult and challenging. Bisphosphonates have been administered for the treatment of osteoporosis for many years, but they are administered with caution in those who have renal failure. With the introduction of Prolia as an anti-osteoporosis drug, the hope was created to treat patients with kidney failure.
Please cite this paper as: Karimifar M, Karimifar M. Anti-receptor activator nuclear factor κ-B ligand (anti-RANKL) as an antiresorptive agent for renal failure osteoporotic patient. J Parathyr Dis. 2018;6(2):33. DOI: 10.15171/jpd.2018.12.
Copyright © 2018 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.